JP2019506843A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506843A5
JP2019506843A5 JP2018531211A JP2018531211A JP2019506843A5 JP 2019506843 A5 JP2019506843 A5 JP 2019506843A5 JP 2018531211 A JP2018531211 A JP 2018531211A JP 2018531211 A JP2018531211 A JP 2018531211A JP 2019506843 A5 JP2019506843 A5 JP 2019506843A5
Authority
JP
Japan
Prior art keywords
polypeptide
pharmaceutical composition
composition according
tcr
genetically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018531211A
Other languages
English (en)
Japanese (ja)
Other versions
JP7082051B2 (ja
JP2019506843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012882 external-priority patent/WO2017123557A1/en
Publication of JP2019506843A publication Critical patent/JP2019506843A/ja
Publication of JP2019506843A5 publication Critical patent/JP2019506843A5/ja
Application granted granted Critical
Publication of JP7082051B2 publication Critical patent/JP7082051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018531211A 2016-01-11 2017-01-10 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法 Active JP7082051B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277442P 2016-01-11 2016-01-11
US62/277,442 2016-01-11
PCT/US2017/012882 WO2017123557A1 (en) 2016-01-11 2017-01-10 Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same

Publications (3)

Publication Number Publication Date
JP2019506843A JP2019506843A (ja) 2019-03-14
JP2019506843A5 true JP2019506843A5 (https=) 2020-02-13
JP7082051B2 JP7082051B2 (ja) 2022-06-07

Family

ID=59311424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018531211A Active JP7082051B2 (ja) 2016-01-11 2017-01-10 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法

Country Status (9)

Country Link
US (1) US11814679B2 (https=)
EP (1) EP3402512A4 (https=)
JP (1) JP7082051B2 (https=)
KR (1) KR20180101417A (https=)
CN (1) CN108697776A (https=)
AU (1) AU2017207282A1 (https=)
CA (1) CA3008287A1 (https=)
MX (1) MX2018007295A (https=)
WO (1) WO2017123557A1 (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
EP4491237A3 (en) 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
MX2019004775A (es) 2016-11-03 2019-08-05 Squibb Bristol Myers Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
KR102775647B1 (ko) 2017-03-31 2025-03-06 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
US20210340250A1 (en) 2017-05-30 2021-11-04 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
US11351163B2 (en) 2017-09-29 2022-06-07 Bristol-Myers Squibb Company Compositions and methods of treating cancer
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
EP3706778A1 (en) 2017-11-06 2020-09-16 Bristol-Myers Squibb Company Methods of treating a tumor
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
JP2021511344A (ja) 2018-01-22 2021-05-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌を治療する組成物および方法
CA3096287A1 (en) 2018-01-22 2019-07-25 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
EP3768699B1 (en) * 2018-03-23 2025-11-12 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
JP7680208B2 (ja) 2018-04-04 2025-05-20 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ２７抗体およびその使用
CN112533629A (zh) * 2018-06-19 2021-03-19 阿尔莫生物科技股份有限公司 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
MX2021000726A (es) 2018-07-26 2021-03-25 Bristol Myers Squibb Co Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
US20210301324A1 (en) * 2018-08-24 2021-09-30 Repertoire Genesis Incorporation Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor
WO2020076799A1 (en) 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
JP2022512750A (ja) 2018-10-19 2022-02-07 ブリストル－マイヤーズ スクイブ カンパニー 黒色腫に対する併用療法
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
WO2020117952A2 (en) * 2018-12-05 2020-06-11 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN113891748A (zh) 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
CA3153777A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
US20220339249A1 (en) 2019-09-25 2022-10-27 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
BR112022009631A2 (pt) 2019-12-19 2022-08-09 Bristol Myers Squibb Co Combinações de inibidores de dgk e antagonistas do ponto de checagem
WO2021152548A1 (en) 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
KR20220139915A (ko) 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
US20230235073A1 (en) 2020-03-06 2023-07-27 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
US20230119066A1 (en) 2020-03-23 2023-04-20 Bristol-Myers Squibb Company Anti-ccr8 antibodies for treating cancer
US20210393743A1 (en) * 2020-06-21 2021-12-23 Ketan Desai Use of IL13 for prevention and treatment of COVID19
BR112023003427A2 (pt) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para carcinoma hepatocelular
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
IL302346A (en) 2020-10-28 2023-06-01 Ikena Oncology Inc Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
AU2022320051A1 (en) 2021-07-30 2024-01-25 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
KR20240099362A (ko) 2021-10-29 2024-06-28 브리스톨-마이어스 스큅 컴퍼니 혈액암에 대한 lag-3 길항제 요법
CA3249004A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Polytherapy for Hepatocellular Carcinoma
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
US20260042840A1 (en) 2022-04-07 2026-02-12 Bristol-Myers Squibb Company Methods of treating tumor
US20230326022A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
EP4626552A1 (en) 2022-12-01 2025-10-08 MedImmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
CN120731228A (zh) 2022-12-21 2025-09-30 百时美施贵宝公司 肺癌的组合疗法
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
TW202600608A (zh) 2024-02-27 2026-01-01 美商必治妥美雅史谷比公司 抗ｃｅａｃａｍ５抗體及其用途
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
RU2671897C2 (ru) * 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
GB201319160D0 (en) 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015108785A1 (en) * 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11028143B2 (en) * 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) * 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017048614A1 (en) * 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood

Similar Documents

Publication Publication Date Title
JP2019506843A5 (https=)
ES3053456T3 (en) Interleukin-2-fc fusion proteins and methods of use
JP7556583B2 (ja) Ｋｒａｓ突然変異を識別するｔ細胞受容体およびそのコード配列
TWI727182B (zh) 新型t細胞受體及其免疫治療
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
ES2699320T3 (es) Receptores de linfocitos T para el VIH de alta afinidad
US20220017588A1 (en) Split interleukin mimetics and their use
JP2021525534A5 (https=)
CN109320615A (zh) 靶向新型bcma的嵌合抗原受体及其用途
CN112972666B (zh) 个性化基因修饰肿瘤dc疫苗的制备方法
JP2023138660A5 (https=)
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
CN106478808B (zh) 识别ny-eso-1抗原短肽的t细胞受体
US10029003B2 (en) Methods and materials for treating cancer
EP3786178A1 (en) Tcr constructs specific for ebv-derived antigens
WO2025189685A1 (zh) 一种嵌合抗原受体纳米复合物及其制备方法和在制备抗衰老药物中的应用
CN110964750A (zh) 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途
WO2021022447A1 (zh) 识别afp抗原短肽的t细胞受体
CN109897107B (zh) 纳米抗体及其制备方法
KR101310511B1 (ko) 흉선-특이성 단백질
CN113321736A (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
CN106188274A (zh) 识别rhamm抗原短肽的t细胞受体
WO2021170116A1 (zh) 一种识别afp的t细胞受体
KR20220040489A (ko) T 세포 수용체 및 이의 사용 방법
CN111499766A (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用